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Abstract
Background/Aim: Diabetes-associated myocardial dysfunction results in altered gene expression in the heart. We aimed to
investigate the changes in gene expression profiles accompanying diabetes-induced cardiomyopathy and its phenotypic
rescue by restoration of SERCA2a expression.
Methods/Results: Using the Otsuka Long-Evans Tokushima Fatty rat model of type 2 diabetes and the Agilent rat
microarray chip, we analyzed gene expression by comparing differential transcriptional changes in age-matched control
versus diabetic hearts and diabetic hearts that received gene transfer of SERCA2a. Microarray expression profiles of selected
genes were verified with real-time qPCR and immunoblotting. Our analysis indicates that diabetic cardiomyopathy is
associated with a downregulation of transcripts. Diabetic cardiomyopathic hearts have reduced levels of SERCA2a. SERCA2a
gene transfer in these hearts reduced diabetes-associated hypertrophy, and differentially modulated the expression of 76
genes and reversed the transcriptional profile induced by diabetes. In isolated cardiomyocytes in vitro, SERCA2a
overexpression significantly modified the expression of a number of transcripts known to be involved in insulin signaling,
glucose metabolism and cardiac remodeling.
Conclusion: This investigation provided insight into the pathophysiology of cardiac remodeling and the potential role of
SERCA2a normalization in multiple pathways in diabetic cardiomyopathy.
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Introduction
Cardiovascular disease is the leading cause of death in diabetic
patients [1]. Both clinical and experimental studies have shown that
diabetes-induced cardiomyopathy is an important contributing
factor of heart failure in diabetic patients independent of
atherosclerosis, hypertension, and other complications [2–4].
Severalmetaboliccomplications, accompanied by insulindeficiency
or impaired insulin responsiveness and calcium handling abnor-
malities, are common to both types 1 and 2 diabetes [5,6]. The
genetic and cellular mechanisms underlying the pathophysiology of
diabetes-induced cardiomyopathy have been explored extensively
in animal models. These animals have characteristic abnormalities
that include altered functional activity of ion channels and pumps
and changes in gene expression of regulatory and modulatory
proteins of excitation-contraction coupling [7–12].
Previous studies show the impairment of SR function in diabetic
cardiomyopathy is caused by reduced activity of the SR calcium
pump (SERCA2a) due primarily to a decrease in SERCA2a
expression [10,13–15] and a 2–4 fold increase in expression of
phospholamban (PLB) [10]. With a decrease in SERCA2a
expression and an increase in PLB expression, the SERCA2a/
PLB ratio is significantly decreased, leading to a slower relaxation.
In neonatal rat myocytes in vitro, overexpression of SERCA2a
largely rescued the phenotype created by increasing the SER-
CA2a/PLB ratio [16]. In human cardiomyocytes isolated from the
left ventricle of patients with end-stage heart failure, gene transfer
of SERCA2a resulted in an increase in both protein expression
and pump activity, and induced a faster contraction velocity and
enhanced relaxation velocity, thereby restoring these parameters
to levels observed in nonfailing hearts [17]. In a rat model of
pressure-overload hypertrophy in transition to failure, where
SERCA2a protein levels and activity are decreased and severe
contractile dysfunction is present, overexpression of SERCA2a by
gene transfer in vivo restored both systolic and diastolic function to
normal levels [18,19]. Normalization of calcium handling also
improved survival, normalized altered myocardial metabolism and
intracellular signaling pathways [18], and abrogated ventricular
arrhythmias [20]. Transgenic diabetic mice overexpressing
SERCA2a were also found to have improved cardiac contractile
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2+ handling compared to diabetic wild type
mice [21]. Recently, we showed in a type 2 diabetic model that
diabetes is associated with cardiac energy wasting with regard to
Ca
2+ regulation. This energy mishandling is demonstrated by the
high myocardial oxygen consumption to support left ventricular
contractility, which contributes to the contractile dysfunction
observed in diabetic cardiomyopathy [22]. Myocardial gene
transfer of SERCA2a in these diabetic subjects restored the
oxygen cost of left ventricular contractility, as well as contractile
dysfunction, to non-diabetic levels [22]. Therefore, SERCA2a
appears to improve not only mechanical but also energetic
function of the diabetic myocardium by transforming inefficient
energy utilization into a more efficient state, in addition to
restoring diastolic and systolic function to normal.
Collectively, the positive effects produced by SERCA2a
correlate with transcriptional changes that may provide important
clues as to the critical pathways involved in cardiac function. In
this study we aimed to: 1- explore the changes in gene expression
profiles accompanying type 2 diabetes-induced cardiomyopathy
and to identify molecular and cellular signaling pathways and
genes that may contribute to cardiac remodeling as a result of the
disease; and 2- examine the transcriptional changes induced by
SERCA2a gene transfer into diabetic hearts and to differentiate
between SERCA2a-regulated and diabetes-regulated genes. Func-
tional analysis of the obtained transcriptional profiles indicated
that SERCA2a restoration is associated with changes in cellular
energetics and metabolism, in calcium handling and in intracel-
lular signaling pathways.
Materials and Methods
Construction of recombinant adenoviruses
For the generation of E1 deleted SERCA2a and b-galactosidase
(b-Gal) adenoviruses we used the pAdEasy-1 adenoviral plasmid
and the pAdTRACK shuttle vector, containing green fluorescent
protein (GFP) under the control of the CMV promoter. The
Adenovirus b- galactosidase (Ad.b-Gal) was used as a control. The
titers of stocks used in these studies measured by plaque assays
were 5.9610
10 pfu/ml (Ad.SERCA2a) and 4.5610
10 pfu/ml
(Ad.b-Gal), with a particle/pfu ratio of 40:1. Wild-type adenovirus
contamination was excluded by the absence of PCR-detectable
early region 1 (E1) sequences.
Animals
Five-week-old male diabetic Otsuka Long-Evans Tokushima
Fatty (OLETF) and normal male Long-Evans Tokushima Otsuka
(LETO) rats were obtained from Tokushima Research Institute,
Otsuka Pharmaceutical Company (Tokushima, Japan). The
OLETF is an established model of spontaneous non-insulin-
dependent type 2 diabetes mellitus (DM) that manifests stable
clinical and pathological features that resemble human type 2 DM.
The model is characterized by hyperinsulinemia from 8 weeks of
age, insulin resistance of the peripheral tissues from 12 weeks of
age, late onset of hyperglycemia after 20 weeks of age, and
diagnosable DM by oral glucose tolerance test (OGTT) from 25
weeks of age [23,24]. Furthermore, the OLETF rats (60–66 weeks
of age) develop significant slowing of isovolumic LV relaxation rate
with depressed expression of cardiac SERCA2a protein [25].
Adenoviral delivery protocol
Sixty to sixty five week-old OLETF rats, with clear systolic and
diastolic dysfunction, were randomized into 3 groups: diabetic
group with no gene transfer (DM), diabetic group with adenoviral
SERCA2a gene transfer (DM+Ad.SERCA2a), and diabetic group
with adenoviral b-galactosidase gene transfer (DM+Ad.b-Gal).
LETO rats served as non-diabetic control animals. The adenoviral
delivery system has been described previously [26]. Four to six
days after adenoviral transduction, the hearts were harvested,
separated into right or left ventricles, weighed and then frozen in
liquid nitrogen and stored at 280uC.
Preparation of cRNA, direct labeling and oligonucleotide
array hybridization
Total RNA (1 mg), isolated from LETO and OLETF hearts
transduced with Ad.SERCA2a or Ad.b-Gal, was amplified and the
cyanine-3/cyanine-5 labeled CTP was incorporated using T7
RNA polymerase. Equimolar amounts of cRNAs from control
(labeled with Cy5) and DM, DM+SERCA2a or DM+b-Gal
(labeled with Cy3) hearts were mixed together and were cleaned
through QIAquick PCR Purification Kit spin columns (Qiagen,
Valencia, CA) to remove unincorporated dye-labeled nucleotides.
The concentration and pmol incorporation was calculated after
absorbance readings were taken at 260, 280, 550 and 650 nm. To
perform reverse labeling, equimolar amounts of oppositely labeled
cRNAs from the infected and uninfected hearts were mixed and
hybridized to a separate microarray slide. The slides were
hybridized, washed and scanned according to Agilent recommen-
dations and settings.
Scanning and Feature Extraction of arrays
Arrays were scanned with Agilent’s G2565AA Microarray
Scanner System and analyzed using Agilent Feature extraction
software (Agilent Technologies), which calculates log ratios and P
values for valid features on each array and provides a confidence
measure of gene differential expression by performing outlier
removal, background subtraction, and dye normalization for each
feature. The software filters features that are not positive and
significant with respect to background or features that are
saturated. It then fits a normalization curve across the array using
the locally weighted linear regression curve fit (LOWESS)
algorithm to detect and correct dye bias.
Analysis of microarray data
Differential expression values are presented as ratio of intensities
between diabetic or diabetic-treated (with SERCA2a or b-Gal)
and control samples. Expression data were omitted in the regions
where no signal was present or if the signal was just above local
background or derived from ,40% of the area of the printed spot.
After normalization of the intensities, the data were filtered to
exclude spots with intensities less than twice the background (150
pixels) in either channel and finally, only spots with a normalized
ratio greater than 1.5 were considered, since a minimum of 1.4-
fold change in differential expression can be accurately detected
[27]. However, only data with 2 fold-change or higher cutoff
values are presented in these studies. Using the processed data we
then performed in depth data analysis with the Genespring
software (Agilent Technologies). The significantly regulated genes
were grouped into functional categories based on annotation by
Gene Ontology, pathway (KEGG and Ingenuity) analysis and PIR
keywords using Genespring and DAVID version 2007.
Extraction of DM and SERCA2a affected genes
We compared the microarray data among the various groups:
control non-diabetic vs. diabetic (DM); control non-diabetic vs.
DM+SERCA2a; control non-diabetic vs. DM+b-Gal; DM vs.
DM+SERCA2a; DM vs. DM+b-Gal. First, a list of genes
(number=838) differentially expressed (2-fold or more change in
Diabetes-Induced Gene Profile
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Within this list, genes differentially expressed (2-fold or more)
between DM+SERCA2a and DM samples were selected and a
second list of genes was generated using the Venn-diagram
approach. From the latter list, genes that had a more than 2-fold
change in expression level between the DM samples and the
DM+b-Gal group were excluded since they likely represent the
effect of the viral gene transfer. In summary, we first identified the
genes affected by the DM, and among those genes, the ones
affected by SERCA2a gene therapy and we subtracted the effect of
b-Gal from that of SERCA2a to extract SERCA2a specifically-
regulated genes. Differences in gene expression between groups
were evaluated by using the t test with unequal variances.
Annotations were compiled by using Genespring and Ingenuity
softwares.
qRT-PCR analysis and western blotting
Expression of selected genes was determined by using two-step
quantitative real-time PCR. Total RNA (2 mg), from control and
DM hearts, was reverse transcribed using the High Capacity
cDNA Reverse Transcription kit (Applied Biosystems (ABI), Foster
City, CA) according to the manufacturer’s protocol and qPCR was
performed with Power SYBR green PCR Master Mix on an ABI
Prism 7500 Real Time PCR System. Multiple transcripts were
analyzed simultaneously for 40 cycles using an optimized qRT-
PCR thermal profile. Data Analysis was performed using Real-
Time SDS software (ABI). For each set of primers, a no template
control and a no reverse amplification control were included. Post-
amplification dissociation curves were performed to verify the
presence of a single amplification product in the absence of DNA
contamination. Fold changes in gene expression were determined
using the DDCt method with normalization to 18S rRNA
endogenous control.
Following qRT-PCR analysis, corresponding protein changes of
some putative mRNA changes were analyzed by immunoblotting
using standard protocol. Films from at least three independent
experiments were scanned and densities of the immunoreactive
bands were evaluated using NIH Image software.
Protein synthesis rate measurements
Protein synthesis rates in neonatal cardiomyocytes were
determined using [
3H]-Leucine incorporation as described
previously [28]. [
3H]-Leucine incorporation was measured by
scintillation counting (MicroBeta Trilux, PerkinElmer). [
3H]-
Leucine uptakes were measured by stimulating the myocytes with
Ad.SERCA2a or Ad.b-gal (MOI 50) in the presence or absence of
endothelin-1 (100 nM).
Statistical analysis
All values were calculated as mean6SD. Data were compared
by two-tailed Student’s t test. The null hypothesis was rejected for
P,0.05.
Results
Characterization of animals and ventricular function
The Otsuka Long–Evans Tokushima Fatty (OLETF) rat is an
established model of congenital Diabetes Mellitus (DM) which
shows left ventricular (LV) diastolic dysfunction and slowing of
isovolumic LV relaxation rate associated with abnormal calcium
handling and depressed SERCA2a protein expression [23,25].
The development of diabetes was confirmed by a marked increase
in blood glucose levels in all DM rats, measured after 5–6 hours of
fasting, compared to non-DM control animals (Fig. 1A). The body
weights (BW) were not statistically different in all groups (not
shown). The data in figure 1B also show a significant increase in
LV/BW ratio in all DM rats (2.45610
23 g60.1, n=8) compared
with normal rats (1.87610
23 g60.08, n=9, P,0.003), an
indication of cardiac hypertrophy. The mean LV/BW in
DM+SERCA2a group significantly decreased compared to DM
group (2.13610
23 g60.07, n=4, P,0.04) but did not reach the
control levels (Fig. 1B), which may indicate that SERCA2a gene
transfer into diabetic hearts reverses the associated hypertrophy.
Compared to controls, the DM rats showed severe left
ventricular (LV) diastolic and systolic dysfunction. The maximal
rate of LV pressure rise (dP/dt max) and LV pressure fall (dP/dt
min) were significantly decreased in DM group (Fig. 1C & D,
respectively). This observed cardiac dysfunction is likely due to
decreased levels of SECRA2a expression [22] since SERCA2a
gene transfer into DM hearts dramatically reversed these
parameters (dP/dt max 5.4660.59 vs. 2.1560.55 mmHg/msec,
P,0.05; dP/dt min 23.4660.48 vs. 21.5860.28 mmHg/msec,
n=6, P,0.05) (Fig. 1C & D). In addition, SERCA2a transduction
significantly improved the time course of relaxation (tau)
compared to DM hearts (19.662.4 vs 25.065.8 msec, P,0.05)
(Fig. 1E). These data indicate that SERCA2a gene transfer into
DM hearts considerably improved myocardial performance. Of
note, these SERCA2a-mediated improvements were not the result
of viral infection since control virus (b-Gal) did not affect in vivo
cardiac function (Fig. 1C, D & E).
Microarray data analysis
We used Agilent’s 60-mer oligonucleotide two-color dye assay
and quantitative real-time PCR to identify differentially expressed
genes in type 2 diabetic failing hearts and their phenotypic rescue
by SERCA2a restoration. Raw data output was imported into
Genespring GX7.3 (Agilent Technology) and normalized by
setting values below 0.01 to 0.01, normalizing each chip to the
50
th percentile of all measurements in that sample (per chip
normalization), and normalizing each gene to the median
measurement for that gene across all samples (per gene
normalization). To focus on genes with reliable changes in
expression, we filtered the normalized data for signal intensity
with a ratio of $2 for up regulation and a ratio of #0.5 for down-
regulation. We compared the microarray datasets among the
various groups: DM; DM+SERCA2a and DM+b-Gal (Fig. 2).
The diabetic subjects were compared with control subjects. Ad.b-
Gal was used as a viral control vehicle and its effect removed from
that of Ad.SERCA2a to extract SERCA2a specifically-regulated
genes (Fig. 2).
The results reveal a significant divergence in gene expression
among the DM and the two adenoviral treatments (Fig. 2), with a
total of 2078 transcripts being differentially expressed. The data
from the 3 comparisons (DM vs. Cont=838 genes; DM vs.
DM+SERCA2a=661 genes; DM vs. DM+b-Gal=579 genes)
revealed few commonly regulated genes (Fig. 2). Of particular
interest to our laboratory is the set of 76 genes that were co-
regulated by both DM and SERCA2a overexpression. This will
help us explore the nature of genes that are affected by diabetes,
and their nature following phenotypic rescue by SERCA2a
restoration.
Diabetes-induced transcriptional profile
Of the more than 20,000 genes represented on the array, 838
transcripts were differentially expressed between control and
diabetic hearts (Fig. 2). Of 838 genes, 272 were up-regulated and
566 were down-regulated, an indication that diabetes is associated
with a net suppression of gene expression (Fig. 2). A partial list of
Diabetes-Induced Gene Profile
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expression is shown in Table 1. Among the genes that were
significantly up-regulated in diabetes were Retnla, Gjb2, Itga, Slit
and Dusp6, and among the genes that were down-regulated were
Krueppel-like factor 8, IGFBP, Ngfg, Foxa3, Kcnc2 and Dlp8.
Gene Ontology (GO) analysis confirmed these findings with
Figure 1. Cardiac structural and functional parameters in the different experimental animal groups. (A) Blood glucose levels. Diabetes
(DM) induced a sharp increase in glucose levels which remained high even after viral infection with SERCA2a and b-gal transgenes. (B) LV/BW ratio
calculated based on the LV weight and the final weight of the animal (prior to death). Changes in contractility (dP/dt max) (C), in relaxation (dP/dt
min) (D) and in tau (E) in the different groups. All data shown as means6SD. LV, left ventricle; BW, body weight.
* P,0.05 Control vs. DM;
# P,0.01
DM vs. DM+SERCA;
{ P,0.05 DM+b-Gal vs. DM+SERCA; ˆ P=0.04 DM+SERCA vs. DM+b-Gal.
doi:10.1371/journal.pone.0006474.g001
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ment, intracellular signaling, proliferation and transcription. These
processes are overrepresented as some of the most significant terms
for the diabetes class with P values,0.05 (see below).
Gene Ontology analysis and pathway identification of
diabetes-induced transcripts
Using the Gene Ontology (GO) database, we categorized the
838 differentially expressed genes into known or probable
functional categories (Table 2). The GO Biological Process
category with the highest number of differentially expressed genes
was development (77 genes, 15.78%), consistent with an active
diabetes-induced cardiac remodeling process. Genes like fibroblast
growth factor receptor 1, syntrophin, transcription factor EC,
fibronectin 1 and slit homolog 3 were classified in this group.
Genes involved in response to stress, immune response and
response to wounding were also significantly represented in GO
Biological Process categories, which is consistent with the finding
that diabetic cardiomyopathy is associated with increased stress
levels leading to immune dysregulation that negatively impact the
heart. Genes included in this group were those encoding for
chemokines and those encoding members of the complement
system. The cellular signaling category contained genes like
protein Kinase D2, frizzled homolog 2, dual specificity phospha-
tase 6, mitogen activated protein kinase kinase kinase 10,
adrenergic receptor alpha 2a, and insulin-like growth factor 1,
amongst others. GO Molecular Function analysis showed that cell-
to-cell signaling and interaction, metabolism and energy pathways
were altered, consistent with the observation that diabetes is
closely associated with metabolic dysregulation [29]. In addition,
Ingenuity Pathway Analysis showed that the top cardiotoxicity
functions induced by diabetes are cardiac arteriopathy, cardiac
damage (injury to myocardium) and cardiac hypertrophy (Fig. 3),
which may explain the link between diabetes and cardiac
hypertrophy and heart failure.
SERCA2a-induced transcriptional profile in DM hearts
We were particularly interested to discover changes in LV gene
expression profile following rescue of diabetic cardiomyopathy via
cardiac overexpression of SERCA2a. SERCA2a gene transfer in
diabetic (DM) hearts differentially induced the expression of 76
genes and appears, in general, to reverse the transcriptional profile
induced by diabetes (Fig. 2). Out of the 76 SERCA2a-targeted
genes in DM, 43 are upregulated and 33 are down-regulated. A
list of the most differentially regulated genes is presented in
Table 3.
Gene Ontology and Cluster analysis of SERCA2a-induced
transcripts
The majority of the genes modulated by SERCA2a appear to
be involved in signaling mechanisms. Gene Ontology analysis
confirmed this finding with processes such as ‘‘cell-cell signaling’’
and ‘‘signal transduction’’ mechanism (both overrepresented in the
top genes with P values,0.001) as some of the most significant
molecular functions (not shown). Metabolism and calcium
signaling are also significantly represented. KEGG analysis
showed that SERCA2a-induced transcriptional profile is associat-
ed with significant alterations in the MAPK signaling pathway,
consistent with gene ontology data. Likewise, the analysis against
the Ingenuity database showed that IL-6 signaling, TGF-b and
PPAR signaling, and PI3K/Akt signaling were the most
significantly overrepresented.
K-means clustering analysis classified the SERCA2a-regulated
genes into 4 clusters: genes that were up-regulated (set 1:10 genes)
or down-regulated (set 2:31 genes) by diabetes and reverted back
toward normal expression levels by SERCA2a, and genes that
were down-regulated by diabetes but up-regulated (set 3:12 genes)
or further down-regulated (set 4:23 genes) by SERCA2a
overexpression.
Validation of microarray data following SERCA2a
restoration in diabetic hearts
qRT-PCR was used to verify the oligonucleotide microarray
expression data. The differential expressions of 19 randomly
selected genes identified by microarray were validated. Relative
transcript levels were determined in control non-diabetic and
diabetic hearts compared to diabetic hearts transduced with
SERCA2a. qRT-PCR analysis confirmed that the majority of
genes were statistically differentially regulated (P,0.05) in
DM+SERCA2a samples (Table 4). Although the pattern of fold-
change of many of the genes, as determined by qRT-PCR analysis,
correlated with fold-change reported by microarray analysis, there
weresomediscrepancies inat least5 cases.The greatest discrepancy
was seen in the expression of ryanodine receptor 2 (RyR2), which
was reported as 11.4-fold up-regulated in DM hearts by microarray
analysis compared with a modest 1.19-fold by qRT-PCR
(Table 4).The second major discrepancy was observed in the
expression levels of GLUT4, which was reported as 1.30-fold up-
regulated by microarray analysis compared with 0.21-fold down-
regulation by qRT-PCR (Table 4) in DM samples. GLUT4
expression is widely reported to be down-regulated in the diabetic
heart, consistent with our qRT-PCR data. Immunoblotting of
GLUT4 protein expression confirmed this observation (Fig. 4) in
deference to the microarray data. The other discrepancy between
qRT-PCR and microarray was seen with the relative expression of
Figure 2. Venn diagram representing the sets of transcripts
comparison. Seventy six genes were differentially regulated by DM
and SERCA2a. Also shown are the total numbers of genes differentially
modified in the 3 experimental conditions. DM, hearts with diabetes
mellitus; DM+SR, diabetic hearts infected with Ad.SERCA2a; DM+Gal,
diabetic hearts infected with Ad.b-Gal.
doi:10.1371/journal.pone.0006474.g002
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Up-regulated genes
Systematic Name Gene Name Description Fold change P value
NM_053333 Retnla Resistin-like alpha 54.03 0.0487
NM_001004099 Gjb2 Gap junction membrane channel protein beta 2 9.2 0.011
NM_017327 Gnao Guanine nucleotide binding protein, alpha o 5.75 0.022
XM_220398 LOC303113 Similar to FLJ00195 protein 5.21 3.00E-04
NM_030994 Itga1 Integrin alpha 1 4.69 0.109
BC088446 Nostrin Dab2-interacting protein 2/nitric oxide synthase trafficker 4.37 0.0289
NM_016994 C3 Complement component 3 4.03 0.027
NM_040669 Hps1 Hermansky-Pudlak syndrome 1 homolog (human) 3.99 0.0237
NM_183330 Ctsz Cathepsin Y 3.92 0.0455
NM_012569 Gls Glutaminase 3.89 0.05
NM_052809 Cdo1 Cytosolic cysteine dioxygenase 1 3.88 0.0346
XM_235156 LOC314843 Similar to vascular endothelial protein tyrosine phosphatase 3.75 0.0491
NM_022698 Bad Bcl2-associated death promoter 3.73 0.0495
NM_147207 Vof16 Ischemia related factor vof-16 3.69 0.0042
XM_238467 isg12(b) Hypothetical LOC299269 3.65 0.001
NM_031321 Slit3 Slit homolog 3 (Drosophila) 3.63 0.0147
NM_001002805 C4-2 Complement component 4, gene 2 3.63 0.0149
NM_031531 Spin2c Serine protease inhibitor 3.39 0.0473
NM_181384 Tnfsf9 Tumor necrosis factor (ligand) superfamily, member 9 3.29 0.0499
NM_053667 Lepre1 Leprecan 3.26 0.0237
NM_030829 Gprk5 G protein-coupled receptor kinase 5 3.25 0.0305
NM_001004253 Syap1 SYAP1 protein 3.19 4.00E-04
U42627 Dusp6 Dual-specificity protein tyrosine phosphatase (rVH6) 3.18 0.0466
NM_138882 Pspla1 Phosphatidylserine-specific phospholipase A1 3.18 0.0428
NM_021760 Col5a3 Collagen, type V, alpha 3 3.16 0.0259
Down-regulated genes
Systematic Name Gene Name Description Fold change P value
XM_228805 LOC302582 Similar to Krueppel-like factor 8 0.258 0.0064
NM_012595 Ldhb Lactate dehydrogenase B 0.254 0.0017
XM_214266 Tnnc1 Similar to troponin C, cardiac muscle - 0.251 0.0176
NM_053329 Igfals Insulin-like growth factor binding protein, acid labile subunit 0.241 0.113
NM_017239 Myh6 Myosin heavy chain, polypeptide 6 0.227 0.0191
S74398 S74398 L-type Ca2+channel alpha 1 subunit 0.215 0.0185
X04240 Mor1 Mitochondrial malate dehydrogenase 0.214 0.0243
NM_031523 Ngfg Nerve growth factor, gamma 0.213 0.0460
NM_017077 Foxa3 Forkhead box A3 0.211 0.0258
NM_019207 Neurod3 Neurogenic differentiation 3 0.211 0.0259
NM_022217 Amph1 Amphiphysin 0.21 0.0261
NM_022850 Dpp6 Dipeptidylpeptidase 6 0.209 0.0263
NM_053867 Tpt1 Tumor protein, translationally-controlled 1 0.208 0.0292
M59313 Kcnc2 Potassium channel Kv3.2c 0.207 0.03
NM_021841 Gabra6 Gamma-aminobutyric acid A receptor, alpha 6 0.206 0.0313
XM_238787 LOC308516 Similar to Rhophilin-2 0.204 0.0338
XM_236415 LOC315824 Similar to Bone morphogenetic protein 5 precursor 0.203 0.0327
XM_228058 Dlp8 Dynein-like protein 8 0.197 0.033
XM_221672 Tiam1 Similar to invasion inducing protein 0.181 0.0466
NM_031044 Hnmt Histamine N-methyltransferase 0.174 0.0308
NM_054000 Kcnb2 Potassium voltage gated channel, Shab-related subfamily, member 2 0.173 0.0357
Diabetes-Induced Gene Profile
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Cacnb3, although displayed on the microarray, were not amplified
by qRT-PCR. Nevertheless, the qRT-PCR results are in general
concordance with the microarray data and serve to verify the
results. The variations observed could be due to the differences in
the techniques and/or the sequences of oligonucleotide probes used
in the two approaches.
For further secondary validation of the microarray data we
carried out western blot analysis for several proteins. Data
obtained by immunoblotting for these proteins (Fig. 4) involved
in a variety of functions, were qualitatively concordant with that
found by the microarrays and qRT-PCR (Table 4) with the
exception of GSK3b which appears to be unchanged.
Effect of SERCA2a on transcript levels in isolated
cardiomyocytes in vitro
We examined whether the expression of selected transcripts was
directly regulated by SERCA2a overexpression, with b-Gal
serving as a control, in adult rat ventricular myocytes. Cardiomy-
ocytes were infected with Ad.SERCA2a and Ad. b-Gal for
48 hours and the expression levels of Akt, PI3K, GLUT4, S100a3,
MMP7, and CK were determined by qRT-PCR (Fig. 5). The
analysis showed that SERCA2a significantly induced the expres-
sion of all molecules examined except MMP-7, which is increased
in diabetic cardiomyocytes and down-regulated by SERCA2a to
normal levels. Normal non-diabetic cardiomyocytes express low
levels of MMP-7 which are not changed by SERCA2a.
Effect of SERCA2a on cardiac hypertrophy
Hemodynamics measurements (Fig. 1B, C & D) suggest that
SERCA2a gene transfer into DM hearts considerably improved
myocardial performance as indicated by the reversal of the
associated hypertrophy following SERCA2a restoration. We
therefore sought to evaluate the effect of SERCA2a on cardiac
hypertrophy by investigating whether SERCA2a could modulate
any phenotypic changes characteristic of the hypertrophic
response, such as enhanced protein synthesis, induction of classical
fetal genes (i.e. atrial natriuretic factor (ANF) and b-myosin heavy
chain (b-MHC)) and activation of the calcineurin/NFAT pathway
[30]. To this end, hypertrophy of neonatal rat cardiac myocytes in
culture was obtained after stimulation with endothelin 1 (ET-1).
Compared to control, SERCA2a overexpression in ET-1
stimulated myocytes significantly inhibited protein synthesis as
measured by [
3H]-leucine uptake (Fig. 6A) and significantly
decreased the mRNA expression of ANF and b-MHC (Fig. 6B &
C). We show for the first time that expression of SERCA2a
markedly reduced the observed ET-1-induced NFATc1 expression
(Fig. 7A). Furthermore, SERCA2a substantially reduced the basal
level of NFATc1 expression even in the absence of ET-1
stimulation (Fig. 7A). Likewise, the expression of calcineurin was
also significantly decreased by SERCA2a overexpression (Fig. 7A)
compared to controls. The abrogation of ET-1-induced NFATc1
and calcineurin by SERCA2a transgene was confirmed by
manipulating the expression of these molecules with the highly
selective inhibitor of calcineurin/NFAT, VIVIT, and Cyclosporin
A (CsA). Similar to SERCA2a, neonatal myocytes incubated with
CsA (10 mM) or infected with adenoviral vectors carrying the
VIVIT peptide substantially reversed ET-1-induced NFATc1 and
calcineurin expression (Fig. 7A). Quantitative analysis of three to
four separate determinations is depicted in Fig. 7B (calcineurin)
and Fig. 7C (NFAT) normalized to GAPDH. These data indicate
that SERCA2a can target the calcineurin/NFAT pathway and
may modulate this pathway through its effect on intracellular Ca2
needed for calcineurin activation [30].
Discussion
The overall goal of this study was to identify the underlying
alterations in gene expression associated with cardiomyopathy in
type 2 diabetes. The development of diabetic cardiomyopathy
and the cellular and molecular perturbations associated with the
pathology are complex and multifactorial. These diabetes-related
alterations and their cross-interactions can in turn alter signal
transduction and gene expression. It is challenging to define the
precise factors that regulate gene expression in diabetic
cardiomyopathy in vivo since the changes observed can be
induced by diabetes or diabetes-related abnormalities. In the
present study, genomic profiles of heart tissues isolated from non-
diabetic rats (LETO) and diabetic rat model of type 2 diabetes
(OLETF) were analyzed. In addition, insights into the nature and
l e v e lo fd i f f e r e n t i a lm y o c a r d i a lg e n ee x p r e s s i o nf o l l o w i n g
normalization of SERCA2a expression in these diabetic hearts
were also gained.
Type 2 diabetes-induced gene expression changes in
cardiomyopathy
The data show that diabetes has differentially induced the
expression of 838 genes that take part in many cellular processes.
Our analysis indicates that diabetic cardiomyopathy is associated
with a net downregulation of transcripts (272 up- and 566 down-
regulated). The analyses also indicate that diabetic cardiomyop-
athy in type 2 diabetic rats is markedly associated with changes in
genes known to be involved in immune response, development,
intracellular signaling, proliferation and transcription. These
findings are consistent with known diabetes-induced cellular and
molecular cardiac changes, such as structural, metabolic and
signaling perturbations [5].
Of particular interest is the observation that diabetes induced
high expression levels of resistin-like alpha in the heart. Resistin, a
novel hormone that is mainly secreted by adipose tissues in
Down-regulated genes
Systematic Name Gene Name Description Fold change P value
XM_215287 Kif11 Kinesin-like 1 0.152 0.0369
NM_053364 Plfr Proliferin-related protein 0.149 0.0367
AF169825 Chd8 b-Catenin binding protein/chromodomain helicase DNA binding protein 8 0.134 0.0423
NM_013191 S100b S100 protein, beta polypeptide 0.117 0.0372
doi:10.1371/journal.pone.0006474.t001
Table 1. Cont.
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Term Count % P Value
Biological Process
development 77 15.78% 0.0064
response to stress 46 9.43% 8.55E-04
defense response 45 9.22% 1.58E-05
cell adhesion 36 7.38% 3.87E-07
cell differentiation 36 7.38% 0.0081
intracellular signaling cascade 34 6.97% 0.0182
cell-cell signaling 33 6.76% 3.23E-04
response to external stimulus 30 6.15% 1.14E-04
response to wounding 29 5.94% 4.34E-06
cell proliferation 29 5.94% 0.0047
cell motility 19 3.89% 0.0067
cell migration 15 3.07% 0.0053
cell activation 12 2.46% 0.0074
muscle contraction 11 2.25% 0.0045
induction of apoptosis 11 2.25% 0.0202
nucleotide metabolism 11 2.25% 0.0310
ion homeostasis 10 2.05% 0.0445
transmembrane receptor protein tyrosine kinase signaling pathway 9 1.84% 0.05
Cellular Components
extracellular region 88 18.03% 4.42E-06
plasma membrane 70 14.34% 0.0019
intrinsic to plasma membrane 43 8.81% 0.0061
integral to plasma membrane 42 8.61% 0.0082
extracellular matrix 13 2.66% 0.0169
sarcomere 6 1.23% 0.0127
myofibril 6 1.23% 0.0190
contractile fiber 6 1.23% 0.0347
Molecular Function
protein binding 129 26.43% 0.0020
ion binding 60 12.30% 0.0417
calcium ion binding 35 7.17% 2.03E-06
receptor binding 26 5.33% 0.0221
electrochemical potential-driven transporter activity 12 2.46% 0.0100
cytokine activity 10 2.05% 0.05
lipid binding 10 2.05% 0.0430
oxidoreductase activity, acting on CH-OH group of donors 8 1.64% 0.0329
hormone activity 8 1.64% 0.0373
phospholipid binding 7 1.43% 0.0354
protein tyrosine phosphatase activity 6 1.23% 0.0485
KEGG Pathway
RNO01430:CELL COMMUNICATION 9 1.84% 0.05
RNO04512:ECM-RECEPTOR INTERACTION 8 1.64% 0.0183
RNO04610:COMPLEMENT & COAGULATION CASCADES 7 1.43% 0.0165
RNO00630:GLYOXYLATE AND DICARBOXYLATE METABOLISM 3 0.61% 0.0396
SP_PIR_Keywords
glycoprotein 75 15.37% 1.33E-06
transmembrane 75 15.37% 1.93E-05
membrane 75 15.37% 4.11E-05
signal 69 14.14% 1.21E-08
Diabetes-Induced Gene Profile
PLoS ONE | www.plosone.org 8 July 2009 | Volume 4 | Issue 7 | e6474rodents, is thought to be responsible for insulin sensitivity
impairment in several rodent models [31]. Recombinant resistin
protein was found to impair insulin action in normal mice and
cultured adipocytes, and immunoneutralization of resistin im-
proved insulin action in mice with diet-induced obesity [32]. In
skeletal muscle cells, resistin was found to regulate the function of
IRS-1, Akt1 and GSK-3b and to decrease GLUT4 translocation
and glucose uptake in response to insulin [33]. In order to
understand what consequences the observed up-regulation of
resistin-like alpha may have on the heart, we recently undertook a
study in which we showed for the first time that resistin induces
cardiac hypertrophy in neonatal cardiomyocytes and contractile
abnormalities in adult cardiomyocytes [34]. This observation may
be important in providing a basis linking diabetes and hypertrophy
and may explain the relevance of the observed high levels of
resistin in the diabetic hearts.
SERCA2a-induced gene expression changes in diabetic
cardiomyopathy
We have recently shown that diabetic cardiomyopathic hearts
have reduced levels of SERCA2a and that myocardial-targeted
expression of SERCA2a in these diabetic hearts improved left
ventricular (LV) mechanical and energetics function [22]. Thus,
we were particularly interested to discover changes in LV gene
expression profile following the rescue of diabetic cardiomyopathy
by cardiac overexpression of SERCA2a. Transcriptional analyses
showed that SERCA2a gene transfer differentially induced the
expression of a subset of genes and appears, in general, to reverse
Term Count % P Value
receptor 37 7.58% 0.0203
hydrolase 31 6.35% 0.02645
calcium 23 4.71% 4.92E-04
transducer 17 3.48% 0.0458
cell adhesion 16 3.28% 6.13E-06
g-protein coupled receptor 16 3.28% 0.0393
phosphoprotein 16 3.28% 0.0457
acetylation 13 2.66% 0.0183
developmental protein 13 2.66% 0.0209
egf-like domain 9 1.84% 0.0062
cytokine 7 1.43% 0.0183
inflammatory response 6 1.23% 0.0012
hormone 6 1.23% 0.0380
sulfation 5 1.02% 0.0021
muscle protein 5 1.02% 0.0306
Categories ascribed to genes were determined from the Gene Ontology (GO) listings found in Genespring, DAVID and Ingenuity. Count represents the number of genes
associated with a specific term. GO annotation may classify genes more than once in any given category.
doi:10.1371/journal.pone.0006474.t002
Table 2. Cont.
Figure 3. Diabetes cardiotoxicity function. Ingenuity analysis of the DM-induced transcriptional profile indicated that diabetes has markedly
impacted cardiac function. P value is the likelihood that a given pathway is associated with a gene set by random chance.
doi:10.1371/journal.pone.0006474.g003
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Up-regulated genes
Gene Name
Fold
Change Common Genbank Functional Classification
A_43_P15881 24.09 Olfactory receptor gene Olr1482 NM_001000026 Signal transduction
A_43_P21854 16.51 Unknown
A_43_P18139 11.96 Myeloid/lymphoid or mixed-lineage leukemia 2 XM_343326 Cell growth and/or Maintenance
A_43_P16951 9.67 Unknown
A_42_P758644 8.322 HUMCOLVIIA type VII collagen
A_43_P15539 7.026 Interleukin 8 receptor, alpha NM_019310 Cell-cell Signaling
A_42_P692126 6.569 Secretogranin 2 NM_022669 Calcium ion binding/chemo-attractant activity/
Cytokine activity
A_43_P18005 5.864 Unknown
A_43_P19121 5.674 Similar to WD repeat membrane protein XM_223412; Intracellular protein transport
A_43_P14794 5.448 Unknown
A_43_P14388 4.815 Unknown
A_42_P456940 4.805 Unknown
A_43_P15963 4.708 Synaptotagmin X NM_031666 Calcium ion binding/transporter activity
A_43_P21893 4.557 Cadherin 16 (predicted) NM_001012055 Cell adhesion/Calcium ion binding
A_43_P21849 3.781 Similar to ovomacroglobulin, ovostatin XM_342764 Metabolism (carbohydrates)
A_43_P19860 3.224 Unknown
A_43_P18464 3.202 Similar to KIAA0774 protein XM_221871 Unknown
A_43_P22576 3.051 Angiotensin/vasopressin receptor XM_577848 Signal transduction
A_43_P16129 3.02 Secreted frizzled-related protein 4 AF220608; Signal transduction/Development/Metabolism
A_43_P21374 2.77 McKusick-Kaufman syndrome protein NM_001008353 Development/Protein folding
A_43_P15978 2.53 Fibroblast growth factor 4 NM_053809 Cell-cell signaling/Growth/Gene expression
A_43_P22200 2.251 Similar to CG2747-PA XM_343061
A_43_P15022 2.249 Phosphoinositide-3-kinase adaptor protein 1 XM_220008 Kinase activity
A_42_P668600 2.203 Neprilysin-like peptidase gamma Hydrolase/Peptidase activity
A_43_P14187 2.103 Calcium channel, voltage-dependent, b 3 subunit NM_012828 Ion transport activity
A_43_P15267 2.074 Murine thymoma viral (v-akt) oncogene homolog 2 (akt2) NM_017093 Signal transduction
Down-regulated genes
Gene Name
Fold
Change Common Genbank Functional Classification
A_43_P12399 0.476 Huntingtin-associated protein 1 U38373 Cytoskeleton organization/Transport
A_43_P22229 0.362 Similar to RIKEN cDNA D430039N05 gene XM_575160
A_43_P15400 0.337 Breast cancer 1 NM_012514 Apoptosis/Transcription/Metabolism
A_43_P20674 0.308 Similar to RIKEN cDNA 6030404E16 (predicted) XM_343366
A_43_P22798 0.308 Unknown
A_43_P11676 0.254 Trefoil factor 3 NM_013042 Signal transduction
A_43_P19573 0.117 Similar to 2810453L12Rik protein (predicted) XM_227619
A_42_P677354 0.0707 Sodium channel, voltage-gated, type 8, alpha polypeptide NM_019266 Transport activity
A_43_P16076 0.0707 Unknown
A_43_P11351 0.0707 Unknown
A_42_P774782 0.0707 Potassium inwardly-rectifying channel, subfamily J, member 13 NM_053608 Ion channel activity
A_43_P20000 0.0388 Dermatan sulphate proteoglycan 3 (predicted) XM_235083 Metabolism
A_43_P22206 0.0342 Chemokine (C-C motif) ligand 9 (predicted) NM_001012357 Cell-cell communication
A_43_P15454 0.0297 Neuromedin NM_022239 Regulation of gene expression
A_43_P11807 0.0209 Forkhead box A3 NM_017077 Regulation of gene expression
A_42_P833800 0.0123 Unknown
A_43_P12641 0.00864 Claudin 1 NM_031699 Structural molecule activity
A_43_P16113 0.00552 Protocadherin alpha 3 NM_053941 Cell adhesion/Calcium ion binding
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modulation of many of these genes may have important
physiological effects.
SERCA2a modulates Cardiac Hypertrophy. The
sarcoplasmic reticulum Ca
2+ ATPase (SERCA2a) plays a pivotal
role in intracellular Ca
2+ handling in cardiomyocytes [35], and its
expression is decreased in many models of heart failure including
diabetic cardiomyopathy [10,22,36]. Hemodynamics measurements
(Fig. 1B, C & D) suggest that SERCA2a gene transfer into DM hearts
considerably improves myocardial performance as indicated by the
reversal of the associated hypertrophy following SERCA2a
restoration. To further substantiate this observation we show now
that in vitro overexpression of SERCA2a abrogates cardiac
hypertrophy as evidenced by its significant effect on many
phenotypic markers of the hypertrophic response. SERCA2a
overexpression in cardiomyocytes remarkably decreased endo-
thelin-1 (ET-1)-induced protein synthesis, ANF and b-MHC
expression, as well as calcineurin/NFAT expression. Our in vitro
data are in close agreement with our recent in vivo findings. We
showed that in the OLETF type 2 diabetic rat model, transcoronary
gene transfer of SERCA2a increased coronary blood flow and
lowered the LV weight-to-body weight ratio (LV/BW) mainly by
decreasing cardiomyocyte size [37]. Moreover, we showed that an
adenoviral short hairpin RNA vector (AdV-shRNA) silenced
phospholamban (an endogenous inhibitor of SERCA2a),
significantly normalized the massive pressure overload-induced
cardiac dilation, and significantly reduced cardiac hypertrophy,
cardiomyocyte diameter, and cardiac fibrosis [38]. We also found
that SERCA2a overexpression improved anterior wall thickening
and reduced ventricular arrhythmias in a rat model of ischemia [20].
Down-regulated genes
Gene Name
Fold
Change Common Genbank Functional Classification
A_43_P19694 0.00432 Phosphatidylinositol 3-kinase, catalytic, alpha polypeptide XM_574916 Protein kinase activity
A_43_P11989 0.00393 Gap junction membrane channel protein beta 3 NM_019240 Cell communication/Transport
A_43_P19821 0.000917 Similar to calmegin (predicted) XM_222484 Calcium binding/Chaperone activity
doi:10.1371/journal.pone.0006474.t003
Table 3. Cont.
Table 4. Comparisons between fold-change in gene
expression determined by microarray and qRT-PCR methods.
MICROARRAY qPCR
Gene DM DM+SERCA DM DM+SERCA
Akt1 0.87 1.43 0.29 0.74
Akt2 1.02 2.1 0.19 0.77
PI3Ka 1.01 1.41 1.30 3.16
GSK-3b 1.08 0.68 1.10 0.76
PKC-l 1.01 1.65 0.88 1.68
GLUT1 0.94 0.68 1.27 0.61
GLUT4 1.30 1.72 0.21 0.91
CK 0.88 1.41 0.59 2.14
Serca2a 0.79 1.08 0.48 2.21
S100A3 1.80 0.68 2.63 1.15
CaBP1 1.13 0.12 1.96 0.98
RyR2 11.4 0.05 1.19 0.94
Cacna1c 1.05 1.55 0.60 1.12
Cacnb3 0.29 0.62 N/A N/A
MMP7 1.63 0.13 7.08 0.65
FZD4 2.32 0.43 1.50 0.99
FGF4 0.24 0.62 N/A N/A
sFRP4 0.26 0.78 1.64 2.94
Retnla 54.03 0.27 23.8 0.95
The fold changes in mRNA levels in diabetes (DM) and DM+SERCA2a samples of
selected genes were determined by microarray and RT-qPCR. Transcripts were
selected based on their roles in insulin signaling, energy/metabolism, Ca
2+
handling, structural remodeling and intracellular signaling. CK, creatine kinase;
sFRP4, secreted frizzled-related protein 4; Retnla, resistin-like alpha; Cacna1c,
calcium channel, voltage-dependent, L type, alpha 1C subunit; Cacnb3, calcium
channel, voltage-dependent, beta 3 subunit. N/A, not amplified.
doi:10.1371/journal.pone.0006474.t004
Figure 4. Validation of microarray data by Immunoblotting.
Immunoblotting analysis of selected proteins was performed on
samples from control, DM and Serca2a-transduced hearts. A represen-
tative blot from 2–3 experiments is shown. sFRP4, secreted frizzled-
related protein 4; DSC2, desmocollin 2. GAPDH is also shown to verify
protein loading. Cont, control non-diabetic; DM, hearts with diabetes
mellitus; Serca2a, diabetic hearts infected with Ad.Serca2a; MW,
molecular weight.
doi:10.1371/journal.pone.0006474.g004
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with Ad.SERCA2a (MOI=100) for 48 hours, total RNA extracted and relative transcript expression analyzed in real time by qPCR using gene-specific
primers. Product specificity was confirmed by post-amplification dissociation curve analysis. Ad.SERCA2a increased the expression of all genes (except
MMP-7) thus confirming the effect of SERCA2a on the microarray chip. CK, creatine kinase.
doi:10.1371/journal.pone.0006474.g005
Figure 6. Effects of SERCA2a on phenotypic cardiomyocyte hypertrophy. A) Effect on protein synthesis: The effects of SERCA2a on protein
synthesis were evaluated by measuring the rate of
3H-Leucine incorporation in neonatal control myocytes infected with Ad.b-gal and myocytes
infected with Ad.KChIP2 in the presence (+) or absence (2) of ET-1 stimulation (100 nM). B) Effect of SERCA2a on (B) ANF and (C) b-MHC expression in
the presence (+) or absence (2) of ET-1 stimulation (100 nM). SERCA2a overexpression significantly blocked the pronounced increase in ET-1-induced
3H-Leucine incorporation, ANF and b-MHC expression.
doi:10.1371/journal.pone.0006474.g006
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important regulator of cardiac hypertrophy. Furthermore,
SERCA2-induced regression of myocyte hypertrophy may be
mediated, at least, through regulation of the Ca
2+-regulated
phosphatase, calcineurin, which plays a central role in transducing
environmental signals that control gene expression and hypertro-
phic growth in cardiac muscle [30,39]. Increased SERCA2a
activity and/or expression stimulates SR Ca
2+ uptake thereby
diminishing intracellular [Ca
2+] leading to inactivation of the
calcineurin/NFAT signaling pathway.
SERCA2a modulation of Ca
2+ Cycling. In response to
SERCA2a normalization, many genes that were either up- or
down-regulated were restored back to normal levels and many
other genes that were unchanged by the diabetic insult were
differentially altered as determined by K-means clustering analysis.
The observed differential gene expression following SERCA2a
overexpression raises a genuine question as to whether the
transcriptional effects of SERCA2a within the cardiomyocyte are
direct or occur through SERCA2a’s restoration of intracellular
Ca
2+ homeostasis or other factors. Furthermore, SERCA2a
overexpression and subsequent enhancement of the sarcoplasmic
reticulum (SR) Ca
2+-ATPase activity can lead to changes in
cellular homeostasis and trigger a cascade of molecular cross talk
among genes or cellular compartments.
SERCA2a plays an important role in maintaining Ca
2+
homeostasis in cardiac myocytes. A decrease in SERCA2a levels,
as occurs in failing and diabetic hearts, leads to substantial
accumulation of diastolic Ca
2+ which can provide a stimulus for
the induction of hypertrophy (and potentially failure) since a variety
of kinases, receptor and signaling cascades are directly activated by
Ca
2+oruseCa
2+asacofactor[30,40,41].Therefore,therestoration
of SERCA2a in diabetic hearts has a pleiotropic effect on functional
recovery since normalization ofCa
2+ homeostasismaylead to Ca
2+-
specific gene remodeling. Examples of such an effect are those
observed with the down regulation of ryanodine receptor 2 (RyR2),
S100A3, calcium binding protein 1 (CaBP1) and the up regulation
of calcium channel voltage-dependent L type alpha 1C subunit
(Cacna1c), calcium channel voltage-dependent beta 3 subunit
(Cacnb3) and calsinelin. The effect of SERCA2a on RyR2 is
particularly interesting. Diabetic hearts demonstrate significant
decrease in Ca
2+ transient amplitude and sarcoplasmic reticulum
(SR)Ca
2+load,andanincreaseindiastolicCa
2+[42].Thishasbeen
primarily attributed to defect in SERCA2a function coupled with
abnormal RyR2 activity. Our observation that RyR2 expression is
increased in type 2 DM hearts from OLEFT may explain the rise in
diastolic Ca
2+ due to increased Ca
2+ leaking (release). SERCA2a
restoration, however, normalizes this imbalance in Ca
2+ distribu-
tion, possibly through down-regulation of RyR2 expression.
SERCA2a modulation of insulin signaling pathway and
glucose metabolism. Studies of animal models have
demonstrated that insulin signaling pathways are dysregulated in
the diabetic myocardium. This is confirmed by our observation that
a number of insulin-signaling molecules (PI3K, Akt, Glut4, and
atypical PKCl) were down regulated on the microarray chips in
DM hearts. However, SERCA2a gene transfer in these hearts
reversedtheexpressionprofilesofthesemolecules.Microarray,real-
time PCR and, in some cases, immunoblotting analyses showed
increased levels of PI3K, Akt, Glut4 and PKCl and ndecreased
GSK-3b expression following SERCA2a overexpression.
SERCA2a’s up regulation of Akt in conjunction with GSK-3b
down regulation, possibly through Akt signaling, may induce an
improvement in ventricular function which is generally observed
following SERCA2a overexpression. Furthermore, recent studies
have suggested that SERCA2a and the PI3K/GSK3b pathways
may interact either directly or through a Ca
2+-mediated process
[43]. GSK-3b was found to negatively regulate the expression of
SERCA2a leading to severe systolic and diastolic dysfunction [43],
however,treatmentwithinsulinrestored SERCA2atonormallevels
in diabetic rats [10] and inhibited the activity of GSK-3b through
increased phosphorylation of Akt [44]. The interrelationship of the
effects of SERCA2a and insulin pathway appear to be beneficial to
the myocardium in pathological conditions such as diabetes.
Increasing evidence suggests that impaired cardiac energetics
contribute to the contractile dysfunction of the cardiomyopathic
heart. A key element in this process is the perturbation of the
glucose metabolism which is partially due to dysregulated insulin
signaling. We recently demonstrated that SERCA2a overexpres-
sion in DM hearts improved myocardial bioenergetics [22]. This is
supported by our current findings that SERCA2a up-regulates the
expression of many transcripts involved in energy metabolism, for
Figure 7. SERCA2a inhibits calcineurin/NFAT pathway. The
effect of SERCA2a on calcineurin and NFATc1 expression (A) was
evaluated by Western blotting in neonatal myocytes non-infected
(Cont) or infected with Ad.SERCA2a in the presence (+) or absence (2)
of ET-1. As a comparison, calcineurin and NFATc1 expression was
determined in the presence of SERCA2a (Ad.Serca2a) and calcineurin/
NFAT-specific inhibitor VIVIT (VIVIT) or Cyclosporin A. Quantitative
analysis of mean data (6SEM) of 3 to 4 independent experiments for
Calcineurin (B) and NFAT-c1 (C). GAPDH, an internal loading control, is
used to normalize protein expression.
* P,0.05 Cont+ET-1 vs. Cont;
1 P,0.05 Ad.Serca2a+ET-1 vs. Cont+ET-1
doi:10.1371/journal.pone.0006474.g007
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Akt, operating downstream of PI3K, and Glut4, which are known
to play critical roles in insulin- stimulated glucose transport and
regulation. In addition to Glut-4-mediated glucose uptake,
stimulation of glycolysis can also be enhanced by increasing levels
of fructose-2-6-phosphate through activation of 6-phosphofructo-
2-kinase (PFK-2) [45] and pyruvate dehydrogenase (PDH) through
activation of pyruvate dehydrogenase phosphate phosphatase
(PDHP) [46]. Our microarray data show that SERCA2a has
increased the expression of PFK-2 (1.83 fold) and PDHP (1.7 fold),
as well as glucose phosphate isomerase (1.6 fold), which may
translate into an enhancement of glucose metabolism in the
diabetic heart. These findings are in general agreement with
recent findings that SERCA2a overexpression in transgenic mice
results in increased glucose oxidation [47]. Increasing SERCA2a
expression leading to an increase in Ca
2+ maintenance by the SR
may lead to an effective energy metabolism and subsequently an
improvement in cardiac performance. In fact, ameliorating
calcium homeostasis in failing [26] as well as diabetic hearts
[22] results in improved cardiac metabolism and energetics.
Reciprocally, improving myocardial energetics in hypertrophic
[48] and failing hearts [49] normalized calcium handling.
In summary, we have explored the pattern of gene expression
changes that occur in diabetic heart failure before and after
restoration of the intracellular Ca
2+ homeostasis and contractile
function using in vivo adenoviral gene transfer of SERCA2a. We
have observed that SERCA2a restoration has affected many genes
that are involved in multiple cellular processes. It is very likely that
some of these processes are directly mediated by Ca
2+ and others
are the results of a reprogramming response to intracellular cross
talks among genes or cellular compartments as a result of better
Ca
2+ signaling and sustained changes in sarcoplasmic reticulum
Ca
2+ contents. The differential regulation of these genes may shed
light on the role of SERCA2a and the beneficial effects which
accompany its restoration in diabetic failing hearts.
Limitations
Although the analysis of gene expression using microarray
technology is a powerful technique to improve disease under-
standing, it does have its limitations which are related to tissue
selection, the lack of a unified approach to chip data analysis, the
presentation of vast amounts of results, and the extrapolation and
generalization of the findings [50]. In addition, the outcome of
microarray analysis is sensitive to the design and the number of
probes on the array. We used a microarray chip with
approximately 22,000 printed probes; however, these are not all
rat genes currently known, and therefore, the knowledge obtained
from the present experiments remains incomplete. Another
limitation is represented by the data validation. The vast amount
of genes obtained is by and large more than the validation of the
data, which is limited to selected genes of specific interest.
Another limitation is that our findings represent a snapshot
examination of gene transcriptional profile events in the progression
of diabetic cardiomyopathy. However, valuable information can
still be obtained on the molecular fingerprinting and the potential
dysregulated pathways associated with diabetes-induced cardiac
dysfunction. Confirming these molecular changes is essential before
any definitive conclusion can be drawn to correlate these changes
with the disease. We have chosen a time point after which the
OLETFdiabeticratshaveanovertdiastolicandsystolicdysfunction
with a clear down-regulation of the Ca
2+ ATPase SERCA2a.
Restoring SERCA2a at this time point and evaluating the targeted
transcriptome would be more insightful in understanding its
biological effects. The differential transcriptional changes produced
by diabetes and SERCA2a suggest that the two conditions have
different remodeling effects on the myocardium. However, it would
alsobe interestingto determine the molecular alterations before and
after the onset of systolic and diastolic dysfunction associated with
diabetic cardiomyopathy. Finally, our study examined transcription
changes in whole hearts; thus furtherstudies arewarranted to define
the contribution of individual cardiomyocytes or fibroblasts to the
effect of diabetes on cardiac function.
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